Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.59 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22092148 | 1.00 | MAOB (0.59) | MAOBPLA2G4BGAACYP19A1S1PR1 | |
| SCHEMBL29451164 | 0.89 | PTGS2 (0.58) | MAOBPLA2G4BGAACYP19A1ALDH1A1 | |
| SCHEMBL22092175 | 0.87 | MAOB (0.62) | MAOBPLA2G4BALDH1A1MAPTHTT | |
| SCHEMBL22092174 | 0.87 | MAOB (0.62) | MAOBPLA2G4BALDH1A1MAPTHTT | |
| SCHEMBL10106827 | 0.84 | MAOB (0.55) | MAOBGAAS1PR1ALDH1A1MAPT | |
| SCHEMBL22092365 | 0.84 | S1PR1 (0.62) | PLA2G4BGAAS1PR1ALDH1A1MAPT | |
| SCHEMBL22092363 | 0.84 | S1PR1 (0.62) | PLA2G4BGAAS1PR1ALDH1A1MAPT | |
| SCHEMBL22092154 | 0.83 | MAOB (0.56) | MAOBS1PR1LMNAMAPTNPC1 | |
| SCHEMBL22092153 | 0.83 | MAOB (0.56) | MAOBS1PR1LMNAMAPTNPC1 | |
| SCHEMBL10101959 | 0.83 | NPC1 (0.59) | MAOBS1PR1ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220062215-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CIRCADIAN RHYTHM-RELATED DISORDERS, COMPRISING OXYIMINOMETHYLBENZENE DERIVATIVE AS ACTIVE INGREDIENT | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2022-03-03 | — | — | US | claimed |
| WO-2020122380-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CIRCADIAN RHYTHM-RELATED DISORDERS, COMPRISING OXYIMINOMETHYLBENZENE DERIVATIVE AS ACTIVE INGREDIENT | 고려대학교 산학협력단 | 2020-06-18 | — | — | WO | claimed |
| US-12246002-B2 | Pharmaceutical composition for prevention or treatment of circadian rhythm-related disorders, comprising oxyiminomethylbenzene derivative as active ingredient | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2025-03-11 | — | — | US | disclosed |
| US-20220062215-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CIRCADIAN RHYTHM-RELATED DISORDERS, COMPRISING OXYIMINOMETHYLBENZENE DERIVATIVE AS ACTIVE INGREDIENT | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2022-03-03 | — | — | US | disclosed |
| WO-2020122380-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CIRCADIAN RHYTHM-RELATED DISORDERS, COMPRISING OXYIMINOMETHYLBENZENE DERIVATIVE AS ACTIVE INGREDIENT | 고려대학교 산학협력단 | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062215-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CIRCADIAN RHYTHM-RELATED DISORDERS, COMPRISING OXYIMINOMETHYLBENZENE DERIVATIVE AS ACTIVE INGREDIENT | PER2, CRY1, CRY2 | MAOB 50/4885PLA2G4B 1254/4885GAA 3171/4885 |
| US-12246002-B2 | Pharmaceutical composition for prevention or treatment of circadian rhythm-related disorders, comprising oxyiminomethylbenzene derivative as active ingredient | PER2, CRY1, CRY2 | MAOB 50/4885PLA2G4B 1254/4885GAA 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.